By Fineline Cube 
China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction product developed by a team led by Professor Shu Chang from the National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences, in collaboration with Chinese firm Lifetech Scientific Corporation (HKG: 1302). This groundbreaking product streamlines complex aortic interventions into a single procedure.
Product Components
The product comprises the Ankura Plus in-situ fenestration branch reconstruction main stent and the in-situ fenestration adaptive leak-proof CSkirt branch stent. These components, along with the Futhrough membrane perforation system and Fustar adjustable sheath, form Lifetech Scientific’s globally pioneering “Three-in-One” integrated solution for in-situ fenestration branch reconstruction.
Development Collaboration
The Futhrough membrane perforation system and Fustar adjustable sheath were co-developed by Professor Fu Weiguo of Zhongshan Hospital, Fudan University, and Lifetech Scientific. This collaboration has resulted in a comprehensive solution that simplifies the complex process of aortic interventions.-Fineline Info & Tech